Cyclacel receives Nasdaq delisting notice for equity deficiency; hearing set for Oct 15, 2024

Bio Green Med Solution, Inc.

Nasdaq Staff determined Cyclacel's stockholders' equity was below $2.5M as of June 30, 2024, violating Listing Rule 5550(b)(1).
Company requested a hearing before Nasdaq Hearings Panel, automatically staying any suspension or delisting pending decision.
Hearing scheduled for October 15, 2024; company will present plan to regain compliance with equity rule.
No assurance that hearing will be successful or that company can maintain compliance if listing continues.
If appeal denied or compliance not regained, common and preferred stock subject to delisting from Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.